Sana Biotechnology, a younger and fast-growing Seattle-based biotech, has chosen the San Francisco Bay Space as the positioning for its new biomanufacturing facility.
The gene enhancing and cell remedy firm announced that it’ll develop a 163,000 square-foot manufacturing facility in Fremont, Calif. It plans to make use of the house to supply T cell therapies, human stem cells, and viral DNA to engineer cells.
Sana has workplaces in Seattle, San Francisco and Boston, and is promoting positions in all three areas, on the heels of an enormous 587 million IPO in February.
“The Fremont location permits shut proximity to Sana’s current technical and scientific capabilities and entry to a robust biotechnology expertise base,” Sana mentioned in a press launch. We’ve observe up with Sana to study extra, and can replace this publish once we hear again.
Three-year outdated Sana, led by former executives at Juno, plans to make use of the brand new facility to fabricate merchandise for late-stage medical growth and early industrial merchandise, in accordance with its launch. The corporate at present has a number of pre-clinical applications however has not but entered a product into medical trials.
Competitors for researchers expert in biomanufacturing and different areas might be stiff, and the Bay Space is a a lot bigger, extra established biotechnology hub than Seattle. Biotech corporations have a previous historical past of spinning out in Seattle after which leaving for different areas after acquisition, with the 2014 transfer of Amgen’s Seattle operations after the acquisition of Immunex leaving scars on the biotech neighborhood.
However extra just lately, biotech and pharma corporations are placing roots down within the area. Seagen and Bristol Myers Squibb have manufacturing services within the Seattle space, and right now Lumen Biosciences introduced it would construct a smaller-scale manufacturing plant to develop algae-based therapies in a former bakery. Within the final 12 months, corporations within the Northwest have raised eight.6 billion in enterprise capital, in accordance with a mid-2021 report from CBRE Life Sciences.
Seattle at present has 913,000 sq. toes of life sciences house below building, in accordance with the report. That’s in comparison with 2.eight million sq. toes within the “premier submarkets” of the North and South Peninsula of the Bay Space.
Each areas are driving a biotech increase, with IPOs and venture capital funding at all-time highs.
In a earlier interview with GeekWire, Leslie Alexandre, CEO of the trade commerce group Life Science Washington, mentioned that Washington state must beef up its capacity to teach and prepare a regional workforce.
“This turbo-charged development can be short-lived if we fail to create and put money into a complete, ten-year plan to fulfill the various workforce wants of fast-growing biotech corporations,” she mentioned.